The North American neurological disorder drug industry is growing significantly over the forecast period (2020-2026) owing to the rising prevalence of neurological disorders, rising geriatric population, rapid R&D activities by the players in the region. For instance, in May 2019, Allergan Plc announced to share approximately 29 presentations at the 71st Annual American Academy of Neurology (AAN) Meeting regarding neurological disorders and their treatment options.
Further, in December 2019, Ubrelvy was approved by the US FDA. Ubrelvy is a novel drug manufactured by Allergan Plc for the treatment of neurological disorders especially migraine.
Browse the full report description of "North American Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/north-american-neurological-disorder-drugs-market
Besides, some other players that support the growth of the North American neurological disorder drugs market. Players such as Eli Lilly and Co., Merck & Co. Inc., and Allergan Plc., among others are significantly contributing to the market growth. These players are continuously contributing to the growth of the market by adopting several growth strategies in order to curb a large customer base as well as thrive in such a competitive market.
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
North America Neurological Disorder Drugs Market – Segmentation
By Disorder Type
North America Neurological Disorder Drugs Market – Countries Covered